Dallas, Texas 01/03/2014 (FINANCIALSTRENDS) – Recently a deal was inked between the Biodel Inc (NASDAQ:BIOD) and the Becton, Dickinson for injection system and as a result the stock price of Biodel jumped by an almost 14 percent in the initial pre-market trading. The injection system for which the deal has been made is a BD Uniject SCF Disposable Auto-Disable Injection System.
Biodel also released its recent and last quarter earnings data on 18th December, 2013 and reported an EPS that is earning per share of $0.04 which has beaten the Thomas Reuters estimate of $0.32 by a $0.28 margin. There are many industry analysts who are saying that the Biodel Company will post $0.57 EPS for the current financial year. The 52 week low of Biodel is $1.93 and its 52 week high is $6.08. If we talk about its 50 day moving average then it comes out be around $2.25 and its 200 day moving average settles around $3.52. The current market capitalization of the company is around $ 49.3 million.
Overview of the Biodel Company
Biodel Inc (NASDAQ:BIOD) is a development stage company and recently its director sold around $10,699 value of Biodel stocks. The company is building a pipeline of different insulin based and other peptide hormone based products and with the help of its proprietary formulation technology the company is also producing companion products.
The company also holds vast experience in the field of diabetes drug development and has a clinical expertise and scientific knowledge in the same field. There are many industry analysts who are of the view that in order to make money of this stock you need to keep a long term view because such stocks take some time to perform and once their clinical tests are cleared you can expect a good jump in the share price value of such stocks.